Edwards Lifesciences
Investors shrug off FDA warning letter for Edwards
Investors seemed unfazed by news of a warning letter from the FDA for Edwards Lifesciences (NYSE:EW) over a Utah cardiac surgery systems plant.
EuroZone OKs Medtronic’s CoreValve for valve-in-valve implants
The bulls may have run a little too far with St. Jude Medical
EuroPCR: 1-year results continue to support Edwards’ next-gen Sapien XT valve
Valve-in-valve implantation for failed heart valves shows good short-term results
The short-term results of minimally invasive transcatheter valve-in-valve implantation to treat failed biological heart valve protheses are "excellent," but patients must be closely monitored due to some notable cases of suboptimal systolic-valve performance, according to early data from a multi-center trial.
New share buyback goads Edwards Lifesciences up 7%
Edwards Lifesciences (NYSE:EW) said it plans to buy back another $750 million worth of its own stock during the 2nd quarter, with CEO Michael Mussallem buying another $5 million worth on his own.